SCHEMBL5279488

SCHEMBL5279488

CCOC(=O)Cc1csc(C2CCCCC2)n1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
TDP1 Q9NUW8 1/20 0.57
HPGD P15428 3/20 0.56
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 4/20 0.53
GAA P10253 1/20 0.49
LMNA P02545 1/20 0.47
MAPK1 P28482 3/20 0.46
MAPT P10636 2/20 0.46
HTT P42858 1/20 0.46
TSHR P16473 1/20 0.46
USP2 O75604 1/20 0.46
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730320 0.99 ALDH1A1 (0.58) ALDH1A1TDP1HPGDMEN1KMT2A
SCHEMBL25383120 0.85 MEN1 (0.50) ALDH1A1TDP1HPGDMEN1KMT2A
SCHEMBL5281554 0.81 DNM1L (0.40) ALDH1A1TDP1HPGDMEN1KMT2A
SCHEMBL5284550 0.80 HSD17B10 (0.50) ALDH1A1TDP1HPGDSMN1; SMN2GAA
SCHEMBL12440420 0.80 ALDH1A1 (0.49) ALDH1A1TDP1HPGDMEN1KMT2A
SCHEMBL996638 0.78 SMN1; SMN2 (0.62) ALDH1A1TDP1HPGDMEN1KMT2A
SCHEMBL1245930 0.77 SMN1; SMN2 (0.60) ALDH1A1TDP1HPGDMEN1KMT2A
SCHEMBL1107420 0.75 MEN1 (0.68) ALDH1A1TDP1MEN1KMT2ASMN1; SMN2
SCHEMBL30730344 0.75 ALDH1A1 (0.43) ALDH1A1TDP1HPGDMEN1KMT2A
SCHEMBL999454 0.74 ALDH1A1 (0.66) ALDH1A1TDP1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed
EP-0177353-B1 THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1990-04-11 EP disclosed
US-4725610-A TREATMENT OF HYPERLIPEMIA AND DIABETES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-02-16 US disclosed
EP-0177353-A2 Thiazolidinedione derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1986-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 ALDH1A1 2972/4885TDP1 2633/4885HPGD 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.